Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
Christoph Varenhorst, Agneta Siegbahn(Uppsala University), Stefan James(Uppsala University), David Erlinge(Lund University), Sylvia Olofsson(Uppsala University), Kenneth J. Winters(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Oscar Ö. Braun(Lund University), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Lars Wallentin(Uppsala University)
Cited by 94
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k